ALK and non-small cell lung carcinoma: Indeed, the majority of prognostic scores have been developed in patients receiving radiotherapy such as the RPA, the basic score for brain metastases, the score index for stereotactic radiosurgery of brain metastases (SIR), or the comprehensive prognostic index.4, 5, 6,12,13 The introduction of GPA index, DS-GPA, and recently the Lung-molGPA has gradually paved the way for the incorporation of molecular features (epidermal growth factor receptor and/or ALK) to clinical variables, but still lack validation in large multicenter studies with only ALK+ NSCLC patients.13